INT119506

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.55
First Reported 2004
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 32
Total Number 34
Disease Relevance 23.75
Pain Relevance 3.67

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (Egfr) cell morphogenesis (Egfr) intracellular (Egfr)
enzyme binding (Egfr) cytoplasm (Egfr) signal transducer activity (Egfr)
Anatomy Link Frequency
skin 5
spinal cord 2
chest 2
muscle 1
bladder 1
Egfr (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Pain 69 100.00 Very High Very High Very High
metalloproteinase 3 99.50 Very High Very High Very High
Spinal cord 20 98.68 Very High Very High Very High
Inflammation 179 98.04 Very High Very High Very High
chemokine 19 96.92 Very High Very High Very High
ischemia 3 94.08 High High
Potency 38 91.84 High High
Antihistamine 57 90.08 High High
Angina 1 82.32 Quite High
palliative 2 75.48 Quite High
Disease Link Frequency Relevance Heat
Toxicity 483 100.00 Very High Very High Very High
Wound Healing 33 99.92 Very High Very High Very High
Exanthema 665 99.66 Very High Very High Very High
Paronychia 95 99.66 Very High Very High Very High
Cancer 210 99.48 Very High Very High Very High
Sunburn 19 99.34 Very High Very High Very High
Hypomagnesemia 475 99.06 Very High Very High Very High
Immunotherapy Of Cancer 7 99.04 Very High Very High Very High
Diarrhoea 285 98.84 Very High Very High Very High
Frailty 20 98.82 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
An overall decrease in COX-2, EGFR, Akt, androgen receptor, and cyclin D1 expression was found associated with tumor growth inhibition.
Negative_regulation (decrease) of EGFR
1) Confidence 0.55 Published 2007 Journal Clin. Cancer Res. Section Body Doc Link 17908994 Disease Relevance 0.06 Pain Relevance 0
Hypomagnesemia has emerged more recently as a side effect of EGFR inhibitors and should be considered in patients who develop fatigue and muscle weakness on therapy.
Negative_regulation (inhibitors) of EGFR in muscle associated with hypomagnesemia, muscle weakness and fatigue
2) Confidence 0.54 Published 2010 Journal Current Oncology Section Body Doc Link PMC2901793 Disease Relevance 0.79 Pain Relevance 0
Because telangiectasias and hyperpigmentation usually occur as a result of photosensitivity, patients being treated with an EGFR inhibitor should be counseled to practice sun protection.
Negative_regulation (inhibitor) of EGFR associated with pigment disorder, telangiectasia and sunburn
3) Confidence 0.54 Published 2010 Journal Current Oncology Section Body Doc Link PMC2901793 Disease Relevance 1.00 Pain Relevance 0.05
Inhibition of EGFR results in impaired growth and migration of keratinocytes, and inflammatory chemokine expression by these cells.
Negative_regulation (Inhibition) of EGFR in keratinocytes associated with chemokine and inflammation
4) Confidence 0.54 Published 2010 Journal Current Oncology Section Body Doc Link PMC2901793 Disease Relevance 1.02 Pain Relevance 0.14
Here we show that rats subjected to weight-drop spinal cord injury can be effectively treated by direct delivery of a potent EGFR inhibitor to the injured area, leading to significantly better functional and structural outcome.
Negative_regulation (inhibitor) of EGFR in spinal cord associated with spinal cord
5) Confidence 0.43 Published 2007 Journal J. Neurosci. Section Abstract Doc Link 17567803 Disease Relevance 0.42 Pain Relevance 0.16
Blocking a novel Nogo receptor interacting mechanism and/or effects of EGFR inhibition on astrocytes may underlie these effects.
Negative_regulation (inhibition) of EGFR in astrocytes
6) Confidence 0.43 Published 2007 Journal J. Neurosci. Section Abstract Doc Link 17567803 Disease Relevance 0.41 Pain Relevance 0.15
Recently, it was shown that EGFR inhibitors promote nerve regeneration in vitro and in vivo.
Negative_regulation (inhibitors) of EGFR in nerve
7) Confidence 0.43 Published 2007 Journal J. Neurosci. Section Abstract Doc Link 17567803 Disease Relevance 0.40 Pain Relevance 0.12
The robust effects and the fact that other EGFR inhibitors are in clinical use in cancer treatments make these drugs particularly attractive candidates for clinical trials in spinal cord injury.
Negative_regulation (inhibitors) of EGFR in spinal cord associated with immunotherapy of cancer and spinal cord
8) Confidence 0.43 Published 2007 Journal J. Neurosci. Section Abstract Doc Link 17567803 Disease Relevance 0.59 Pain Relevance 0.16
Inhibiting epidermal growth factor receptor improves structural, locomotor, sensory, and bladder recovery from experimental spinal cord injury.
Negative_regulation (Inhibiting) of epidermal growth factor receptor in bladder associated with pain and spinal cord
9) Confidence 0.43 Published 2007 Journal J. Neurosci. Section Title Doc Link 17567803 Disease Relevance 0.37 Pain Relevance 0.22
ZD1839 (Iressa, gefitinib) is an orally active, small-molecule, epidermal growth factor receptor-tyrosine kinase inhibitor that has shown single-agent efficacy for previously treated advanced NSCLC.
Negative_regulation (inhibitor) of epidermal growth factor receptor-tyrosine kinase associated with non-small-cell lung cancer
10) Confidence 0.42 Published 2004 Journal Semin. Oncol. Section Abstract Doc Link 15206079 Disease Relevance 1.31 Pain Relevance 0.08
This protection was abolished by cotreatment of the metalloproteinase inhibitor (MPI) and the EGFR inhibitor AG1478.
Negative_regulation (inhibitor) of EGFR associated with metalloproteinase
11) Confidence 0.41 Published 2007 Journal Am. J. Physiol. Heart Circ. Physiol. Section Abstract Doc Link 17545478 Disease Relevance 0.32 Pain Relevance 0.43
Immunohistochemical and Western blot analysis were done to determine COX-2, epidermal growth factor receptor (EGFR), Akt, androgen receptor, and cyclin D1 expression.
Spec (determine) Negative_regulation (determine) of epidermal growth factor receptor
12) Confidence 0.40 Published 2007 Journal Clin. Cancer Res. Section Body Doc Link 17908994 Disease Relevance 0.08 Pain Relevance 0
Some patients who undergo treatment with an EGFR inhibitor may experience changes to their hair, most notably an increased growth of the eyelashes (trichomegaly)37,65,66.
Negative_regulation (inhibitor) of EGFR in hair
13) Confidence 0.40 Published 2010 Journal Current Oncology Section Body Doc Link PMC2901793 Disease Relevance 1.06 Pain Relevance 0.19
Patients may be able to continue treatment with an EGFR inhibitor following mild to moderate infusion reactions.
Negative_regulation (inhibitor) of EGFR
14) Confidence 0.40 Published 2010 Journal Current Oncology Section Body Doc Link PMC2901793 Disease Relevance 0.30 Pain Relevance 0.10
The STEPP trial evaluated the differences between pre-emptive and reactive treatments for skin toxicities associated with EGFR inhibition by panitumumab in 58 patients receiving panitumumab plus FOLFIRI or irinotecan-only chemotherapy for second-line treatment of mCRC54.
Negative_regulation (inhibition) of EGFR in skin
15) Confidence 0.40 Published 2010 Journal Current Oncology Section Body Doc Link PMC2901793 Disease Relevance 0.43 Pain Relevance 0
Paronychia associated with EGFR blockade is characterized by an erythematous and painful inflammation of the nail fold, which may swell and form granulation tissue37.
Negative_regulation (blockade) of EGFR in granulation associated with pain, inflammation and paronychia
16) Confidence 0.40 Published 2010 Journal Current Oncology Section Body Doc Link PMC2901793 Disease Relevance 1.26 Pain Relevance 0.47
While there are no clear guidelines for dose-modifications with EGFR inhibitors, in the case of cetuximab, Dranko et al. recommend following the dose-modification regimen recommended for papulomacular rash (Table 5)77,78.


Negative_regulation (inhibitors) of EGFR associated with exanthema
17) Confidence 0.40 Published 2010 Journal Current Oncology Section Body Doc Link PMC2901793 Disease Relevance 1.60 Pain Relevance 0.08
The majority of patients treated with an MoAb EGFR inhibitor for mCRC will experience dermatological side effects, the most common of which is the papulopustular skin rash, which occurs early during the course of treatment and can impact the patient’s quality of life.
Negative_regulation (inhibitor) of MoAb EGFR in skin associated with exanthema
18) Confidence 0.40 Published 2010 Journal Current Oncology Section Body Doc Link PMC2901793 Disease Relevance 0.33 Pain Relevance 0.13
Grade 3–4 diarrhea occurred in up to 28% of patients in trials combining an EGFR inhibitor with chemotherapy (Table 3).
Negative_regulation (inhibitor) of EGFR associated with diarrhoea
19) Confidence 0.40 Published 2010 Journal Current Oncology Section Body Doc Link PMC2901793 Disease Relevance 0.91 Pain Relevance 0
The patient may then be rechallenged with the EGFR inhibitor following reversal of the hypomagnesemia90.


Negative_regulation (inhibitor) of EGFR
20) Confidence 0.40 Published 2010 Journal Current Oncology Section Body Doc Link PMC2901793 Disease Relevance 0.88 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox